Drug Profile


Alternative Names: ABT-493; Next-generation HCV protease inhibitor - AbbVie/Enanta

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator AbbVie; Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Antivirals; Aza compounds; Cyclic ethers; Cyclopentanes; Cyclopropanes; Quinoxalines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 23 Feb 2017 CTP push 249572 (NCT02243293) - trial completed
  • 01 Feb 2017 AbbVie completes a phase II trial in Hepatitis C (Combination therapy, Treatment-experienced, Treatment-naive) in USA, Australia, Canada, France, South Korea, New Zealand, Taiwan and United Kingdom (NCT02243293)
  • 31 Jan 2017 Abbvie completes the MAGELLAN-1 trial in Hepatitis C (Combination therapy, Treatment-experienced) in USA, Australia, France, New Zealand, Puerto Rico, Spain and United Kingdom (NCT02446717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top